BriaCell Reports Outperforming Metastatic Breast Cancer Patients and Standard-Beating Survival Data 55% of BriaCell patients[1] ...
Philadelphia & Vancouver, British Columbia – October 1, 2024 – BriaCell Therapeutics Corp. (Nasdaq: BCTX, ...
Dramatic anti-tumor response includes complete resolution of right temporal lobe brain metastasis in patient with ...
Philadelphia & Vancouver, British Columbia – September 12, 2024 – BriaCell Therapeutics Corp. (Nasdaq: BCTX, ...
Philadelphia & Vancouver, British Columbia – September 11, 2024 – BriaCell Therapeutics Corp. (Nasdaq: BCTX, ...
• Median overall survival of 15.6 months in Phase 2 Bria-IMT™ study patients treated in ...
• BriaCell has received positive feedback from its Pre-Investigational New Drug Application (Pre-IND) meeting with ...
PHILADELPHIA, PA and VANCOUVER, British Columbia, September 9, 2024— BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) ...
Progression free survival (PFS) extended to 9.1 months in ADC resistant patient – quadruple the ...
BriaCell doubles Progression-Free-Survival (PFS) and Clinical Benefit Rate vs historical results in the literature Bria-IMT™ ...
Accessibility Tools